Rezolute 8-K: Unregistered Equity Sales, Officer Changes on Jan 23

TL;DR

**Rezolute just sold unregistered shares and changed officers, watch for leadership impact.**

AI Summary

Rezolute, Inc. filed an 8-K on January 29, 2024, reporting events from January 23, 2024, including unregistered sales of equity securities and information regarding the departure or election of directors and officers, as well as compensatory arrangements. This filing is crucial for investors as it signals potential changes in the company's ownership structure and leadership, which can impact future strategic decisions and stock performance.

Why It Matters

Changes in equity ownership and leadership can significantly influence a company's direction and financial health, directly affecting shareholder value.

Risk Assessment

Risk Level: medium — Unregistered sales of equity can dilute existing shareholder value, and changes in leadership introduce uncertainty regarding future company strategy.

Analyst Insight

A smart investor would closely monitor Rezolute's stock performance and look for further details on the unregistered equity sales and new leadership appointments to assess potential dilution and strategic shifts.

Key Players & Entities

• Rezolute, Inc. (company) — the registrant filing the 8-K
• January 23, 2024 (date) — date of earliest event reported in the 8-K
• January 29, 2024 (date) — date the 8-K was filed
• 001-39683 (other) — Commission File Number for Rezolute, Inc.

Forward-Looking Statements

• Rezolute, Inc. may experience short-term stock volatility due to the unregistered equity sales and leadership changes. (Rezolute, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
• $1 — to Daron Evans at an exercise price of $1.02, in connection with his employment,
• $275,000 — pensation: (i) an annual base salary of $275,000 (ii) eligibility to receive an annual p

Filing Documents

• tm244315d1_8k.htm (8-K) — 35KB
• tm244315d1_ex10-1.htm (EX-10.1) — 33KB
• tm244315d1_ex99-1.htm (EX-99.1) — 14KB
• tm244315d1_ex99-2.htm (EX-99.2) — 13KB
• tm244315d1_ex10-1img001.jpg (GRAPHIC) — 4KB
• tm244315d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• tm244315d1_ex99-2img001.jpg (GRAPHIC) — 3KB
• 0001104659-24-007811.txt ( ) — 304KB
• rzlt-20240123.xsd (EX-101.SCH) — 3KB
• rzlt-20240123_lab.xml (EX-101.LAB) — 33KB
• rzlt-20240123_pre.xml (EX-101.PRE) — 22KB
• tm244315d1_8k_htm.xml (XML) — 4KB

02

Item 3.02 Unregistered Sale of Equity Securities. The disclosure contained in Item 5.02 of this Current Report on Form 8-K regarding the issuance of an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4) in the form of stock options to purchase 275,000 shares (the "Inducement Grant") of Rezolute, Inc. (the "Company") common stock to Daron Evans at an exercise price of $1.02, in connection with his employment, is incorporated by reference. The Inducement Grant is exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof and/or Regulation D promulgated thereunder.

02

Item 5.02 Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On January 23, 2024, the Company's Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company's Chief Financial Officer. Prior to joining the Company, he served as Chief Executive Officer of AlloRock, Inc., a biotechnology company in the cardiometabolic disease space, as well as Chief Executive Officer of Specialty Renal Products, Inc., a medical device company in the dialysis space. Previously, Mr. Evans served as Chief Executive Officer of Nephros, Inc, and Chief Financial Officer of Nile Therapeutics, Inc. Since 2015, Mr. Evans has been Managing Director of PoC Capital, LLC, a fund focused on investing in public life science companies. In connection with Mr. Evans' appointment as Chief Financial Officer of the Company, the Company extended Mr. Evans an employment offer letter (the "Offer Letter"). The Offer Letter provides for the following compensation: (i) an annual base salary of $275,000 (ii) eligibility to receive an annual performance bonus with a target of 50% of Mr. Evans' base salary, on December 31 st of each year; and (iii) the Inducement Grant. The stock options issued as the Inducement Grant will vest and become exercisable as to 25% of the underlying shares on the first anniversary of the grant date, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from the first anniversary of the grant date, subject to his continued employment with the Company on such vesting dates. If the Company is acquired during his employment, all remaining options will automatically vest. All stock awards are subject to recovery to other penalties pursuant to (i) the Company's clawback policy, as may be adopted or amended from time to time, or (ii) any applicable la

01

Item 7.01 Regulation FD Disclosure. On January 23, 2024, the Company issued a press release announcing that the U.K. Medicines and Healthcare products Regulatory Agency has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism. On January 24, 2024, the Company issued a press release announcing the appointment of Mr. Evans as the Company's Chief Financial officer. The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter with Daron Evans 99.1 Press Release, dated January 23, 2024 99.2 Press Release, dated January 24, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: January 29, 2024 By: /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR